Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery

Oligonucleotide therapeutics (ONT) traditionally involve a single targeting moiety per oligonucleotide when conjugated for organ delivery. Multimerization represents a novel approach by connecting multiple ONTs to a single scaffold, thereby influencing the drug's activity and biophysical properties <i>in vivo</i>. Recently, others have demonstrated the efficacy of this strategy, showing enhanced tissue retention and extended silencing with the capability to target multiple genes simultaneously. The investigation of diverse multimeric designs is thus an exciting opportunity to explore the delivery of the ONT. In this study, we engineered a versatile peptide branching unit able to link up to four small interfering RNAs together. We conjugated a GalNAc targeting moiety to these scaffolds for liver hepatocyte delivery and assessed their silencing activity. Our approach was further expanded to explore different peptide architectures (linear versus cyclized) and additional functionalities, including endosomal escape domains and dual target silencing. We then evaluated the constructs via subcutaneous and intravenous (i.v.) administration in mice. Notably, the intravenous administration of multimeric siRNA GalNAc demonstrated potent silencing in the liver and significantly affected liver-to-kidney biodistribution. Our findings suggest that peptides as branching units offer a promising pathway for ONT multimerization, advancing the challenges of drug delivery.

Authors

Institutions

Publication Details

Journal
Bioconjugate Chemistry
Published
2025-05-30
DOI
https://doi.org/10.1021/acs.bioconjchem.5c00156
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery

Rouven Stulz, Peter Gennemark, Mahya Dezfouli, Anders Dahlén et al.
Bioconjugate Chemistry
RNA Interference and Gene Delivery
article

Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery

Rouven Stulz, Peter Gennemark, Mahya Dezfouli, Anders Dahlén, Nicola Guzzi, Naoko Toki, Shalini Andersson, Samir EL Andaloussi, Carolina Tängemo, Quentin Vicentini, Bojana Lazovic, Deepak Bhatt, Dennis Hekman
article en

Abstract

Oligonucleotide therapeutics (ONT) traditionally involve a single targeting moiety per oligonucleotide when conjugated for organ delivery. Multimerization represents a novel approach by connecting multiple ONTs to a single scaffold, thereby influencing the drug's activity and biophysical properties <i>in vivo</i>. Recently, others have demonstrated the efficacy of this strategy, showing enhanced tissue retention and extended silencing with the capability to target multiple genes simultaneously. The investigation of diverse multimeric designs is thus an exciting opportunity to explore the delivery of the ONT. In this study, we engineered a versatile peptide branching unit able to link up to four small interfering RNAs together. We conjugated a GalNAc targeting moiety to these scaffolds for liver hepatocyte delivery and assessed their silencing activity. Our approach was further expanded to explore different peptide architectures (linear versus cyclized) and additional functionalities, including endosomal escape domains and dual target silencing. We then evaluated the constructs via subcutaneous and intravenous (i.v.) administration in mice. Notably, the intravenous administration of multimeric siRNA GalNAc demonstrated potent silencing in the liver and significantly affected liver-to-kidney biodistribution. Our findings suggest that peptides as branching units offer a promising pathway for ONT multimerization, advancing the challenges of drug delivery.

Bioconjugate ChemistryVol. 36(6)
Linköping University (SE), Karolinska University Hospital (SE), Karolinska Institutet (SE), AstraZeneca (Brazil) (BR), AstraZeneca (Italy) (IT), AstraZeneca (Sweden) (SE)
Swedish Cancer Foundation, Stiftelsen för Strategisk Forskning, Novo Nordisk, Vetenskapsrådet, Horizon 2020 Framework Programme, H2020 Marie Skłodowska-Curie Actions
Openalex Percentile: Top 89%
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.